Article citationsMore>>

Allen, M.S., Darling, G.E., Pechet, T.T.V., Mitchell, J.D., Herndon, J.E., Landreneau, R.J., et al. (2006) Morbidity and Mortality of Major Pulmonary Resections in Patients with Early-Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial. The Annals of Thoracic Surgery, 81, 1013-1020.
https://doi.org/10.1016/j.athoracsur.2005.06.066

has been cited by the following article:

• TITLE: Complete Response in Inoperable Stage IIB Squamous Cell Lung Carcinoma after Sequential Radiotherapy and Chemotherapy: A Case Report and Review of the Literature

  AUTHORS: Gyursen Ziyafetova

  KEYWORDS: Non-Small Cell Lung Cancer, Chemotherapy, Radiotherapy

  JOURNAL NAME: Advances in Lung Cancer, Vol.15 No.1, March 19, 2026

  ABSTRACT: Background: This manuscript reports a stage IIB (cT3N0M0) squamous NSCLC case deemed inoperable and treated with definitive radiotherapy followed by carboplatin/paclitaxel, achieving complete metabolic response on PET/CT. The paper then reviews standard management options for stage II NSCLC, emphasizing multidisciplinary decision-making. The main message is that selected inoperable stage II patients may achieve durable control with sequential or concurrent chemoradiation. Patients and Methods: I present a case report of complete therapeutic response in inoperable stage IIB non-small cell lung carcinoma after sequential radiotherapy and chemotherapy and a review of literature. Results: Surgical resection is the cornerstone of treatment and the best option for achieving cure in patients with clinically operable Non-Small Cell Lung Cancer (NSCLC). In circumstances where surgical resection may not be feasible, patients may be presented at a Multidisciplinary Tumour Board for further discussion between surgery, medical oncology, radiation oncology, and palliative care. Whenever possible, patients should be considered for enrollment in clinical trials. Conclusions: Patients with stage II NSCLC who are inoperable or refuse surgery can also have long survival with concurrent or sequential radiotherapy and chemotherapy.